GELS (gelteq.com) Forward P/S Multiple

Corporate emblem and logo of Gelteq (GELS)

Gelteq Limited previously focused on costly prototypes, but is now transitioning toward the commercial licensing of patents. The forward P/S valuation reflects this transformation, where the value 32.60 indicates the current level of market confidence. Business growth relies on gel dosing precision and deals with tech giants, although expansion may be limited by alternative drug delivery methods from major players.

Gelteq Ltd - GELS Forward P/S Multiple (period 10/30/2024 - 11/13/2026)

Summary analytical data breakdowns for gelteq.com (GELS)

- market price and analyst price targets:
Price Chart Gelteq|GELS - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization GELS|GELS - Value Adjusted for Debt and Cash
- issuer book value statistics:
Book Value per Share Gelteq|GELS - Book Capitalization|Market Value to Book Value Ratio gelteq.com|GELS - Aggregate Asset Value
- debt and solvency information:
Debt to Equity Gelteq Limited|GELS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Gelteq|GELS - Company Aggregate Debts|Debts to Book Capitalization GELS|GELS - Long-Term Indebtedness|Company Short-Term Debts Gelteq|Quick Liquidity gelteq.com
- financial results and valuation multiples details:
GELS - Company Net Income|Future Profit Gelteq Limited|GELS - Market Price to Net Income Ratio|Forward P/E Multiple Gelteq|GELS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GELS|GELS - Operating profit before depreciation charges|Net earnings per share for the last 12 months Gelteq|GELS - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months gelteq.com|GELS - Earnings per share growth in current year|Earnings growth forecast for next year Gelteq Limited
- total revenue and sales volume data:
GELS - Company Gross Revenue|Company Projected Revenue Gelteq|GELS - Market Cap to Revenue|Forward P/S Multiple GELS
Fundamental company analysis:Gelteq Limited Inc GELS
Original product of gelteq.com

The forward P/S reflects the ratio of Gelteq Limited (GELS) market capitalization to expected revenue, measuring the premium investors are willing to pay for future operational success. In the context of exclusive B2B developments in gel-based drug delivery, the forward P/S value allows for an assessment of how much the market currently prices in the monetization potential of patented encapsulation technologies.

Main competitors

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|bridgebio.com (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGM Group Limited|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio Xeris Biopharma Inc (XERS)|Forward Price-to-Revenue Multiple Keros Corp KROS|Forward P/S Multiple ARCT (Arcturus Therapeutics)|Forward P/S Multiple etonpharma.com ETON|Kamada - Forward P/S Multiple|Projected Price to Revenue Fulcrum Therapeutics Inc (FULC)|ABEO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Mereo BioPharma Group plc (MREO)|Price-to-Projected Revenue Ratio Protalix BioTherapeutics|Price-to-Projected Revenue Ratio PLRX|Forward Price-to-Revenue Multiple APLT (Applied Therapeutics, Inc.)|Price to Expected Revenue Ratio RNTX|Forward P/S Multiple AYTU (Aytu BioPharma)|Chemomab Therapeutics Ltd (CMMB) - Market Cap to Future Revenue Ratio|SRXH - Price-to-Projected Revenue Ratio|Projected Price to Revenue Polyrizon Ltd (PLRZ)|AEZS (zentaris.com) - Forward Price-to-Revenue Multiple|Cyclo Therapeutics Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Inozyme Pharma Inc.|Price-to-Projected Revenue Ratio RPHM|Forward P/S Multiple CSCI